AUPH$16.05
$16.2
Chart
Performance
Key Stats
AI AUPH Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyA company with strong fundamentals and positive thematic alignment, but facing some technical headwinds. Potential for long-term growth with a cautious short-term outlook.
Thematic
Aurinia Pharmaceuticals operates in the growing autoimmune disease market, benefiting from innovation in targeted therapies.
Fundamental
Solid revenue growth and improving profitability, with a healthy balance sheet. Valuation metrics are mixed, but recent performance is positive.
Technical
The stock is showing positive momentum and is trading above key moving averages, indicating a bullish trend. However, some oscillators suggest potential for short-term consolidation.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 80 |
| Market Demand for Treatments | 85 |
| Regulatory Environment | 70 |
| Partnerships & Collaborations | 75 |
| Healthcare Spending Trends | 75 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 80 |
| Growth | 85 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 75 |
| Volume Confirmation | 70 |
| Support & Resistance | 80 |
| Short-term Oscillators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Positive EPS Surprises
The company has exceeded EPS estimates in the last 4 quarters, with surprise percentages of 60.0%, 162.5%, 566.67%, and 20.05% respectively.
Attractive Forward P/E Ratio
The forward Price-to-Earnings (P/E) ratio is 46.5, which is lower than the trailing P/E of 33.3, suggesting potential for future earnings growth to justify the current price.
Bearish Points (8)
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 6.4, which is significantly higher than the TTM P/S of 31.0, indicating potentially high market expectations.
Negative EPS in Prior Periods
The company reported negative EPS in multiple quarters in 2023 and 2024 (e.g., -0.19 in Q1 2024), highlighting past profitability challenges.
Calendar
July 2025
30
Next Earnings Date
H: $0.20
A: $0.14
L: $0.11
H: 65.50M
A: 64.27M
L: 63.66M
Profile
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Seasonals
Price Target
10.00 USD
The 39 analysts offering 1 year price forecasts for AUPH have a max estimate of 12.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
GSK's Benlysta (belimumab) is a direct competitor and established treatment for lupus nephritis (LN) and systemic lupus erythematosus (SLE), directly competing with Aurinia's former flagship drug, Lupkynis.
Weight: 90
AstraZeneca's Saphnelo (anifrolumab) is approved for SLE and represents a significant market presence in lupus, making it a key competitor in the broader lupus treatment landscape.
Weight: 88
BMY has a robust immunology pipeline and marketed products (e.g., Orencia for autoimmune diseases, Sotyktu), actively pursuing therapies in areas overlapping with Aurinia's former focus.
Weight: 85
J&J's Janssen Pharmaceutical Companies have a strong immunology franchise (e.g., Stelara, Tremfya) with ongoing research and development in various autoimmune conditions, including potential relevance to lupus.